US4948592A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pulsed drug delivery
Assignee: Alza Corp
•
Filing: 1989-02-21
•
Granted: 1990-08-14
•
Expires: 2009-02-21
Abstract
Abstract A dosage form comprising (1) an immediately available dose of a beneficial drug followed by a timed delayed dose of drug, or (2) a timed delayed dose of drug.
Inventors
- 👤 Atul D. Ayer
- 👤 Felix Theeuwes
- 👤 Patrick S. L. Wong
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 18:01
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
150 words
A dosage form for delivering a beneficial drug formulation to an environment of use, wherein the dosage form comprises: (a) a wall comprising in at least a part a composition permeable to the passage of fluid and substantially impermeable to the passage of drug, which wall surrounds: (1) a first layer comprising a dosage amount of a beneficial drug; (2) a second layer comprising a hydrogel that expands in the present of fluid; (3) mean s coated around the first and second layer for delaying the release of the drug from the dosage form; (b) at least one passageway in the wall for releasing the beneficial drug from the dosage form; and, (c) a dosage amount of a beneficial drug in contact with the exterior surface of the wall of the dosage form, with the proviso that said drug is a different drug than the drug in the first layer.
Claim 2
Dependent Claim
150 words
A dosage form for delivering a beneficial drug formulation to an environment of use, wherein the dosage form comprises: (a) a wall comprising in at least a part a composition permeable to the passage of fluid and substantially impermeable to the passage of drug, which wall surrounds: (1) a first layer comprising a dosage amount of a beneficial drug; (2) a second layer comprising a hydrogel that expands in the present of fluid; (3) mean s coated around the first and second layer for delaying the release of the drug from the dosage form; (b) at least one passageway in the wall for releasing the beneficial drug from the dosage form; and, (c) a dosage amount of a beneficial drug in contact with the exterior surface of the wall of the dosage form, with the proviso that said drug is a different drug than the drug in the first layer.
Claim 3
Dependent Claim
142 words
A dosage form useful as a nightime sleep-aid for delivering a first dose and a second dose of diphenphydramine to a recipient, wherein the dosage form comprises: (a) a wall comprising in at least a part a semipermeable composition permeable to the passage of an external fluid and substantially impermeable to the passage of a drug formulation, said wall surrounding; (1) a first layer comprising a second dose of diphenhydramine; (2) a second layer comprising a hydrophilic hydrogel formulation that expands in the presence of fluid; (3) means coated around the first and the second layer for delaying the release of diphenhydramine from the dosage form; (b) at least one exit means in the wall for releasing diphenhydramine from the dosage form; and, (c) a dosage amount of a first dose of diphenhydramine on the exterior wall surface of the dosage form.
Claim 4
Dependent Claim
142 words
A dosage form useful as a nightime sleep-aid for delivering a first dose and a second dose of diphenphydramine to a recipient, wherein the dosage form comprises: (a) a wall comprising in at least a part a semipermeable composition permeable to the passage of an external fluid and substantially impermeable to the passage of a drug formulation, said wall surrounding; (1) a first layer comprising a second dose of diphenhydramine; (2) a second layer comprising a hydrophilic hydrogel formulation that expands in the presence of fluid; (3) means coated around the first and the second layer for delaying the release of diphenhydramine from the dosage form; (b) at least one exit means in the wall for releasing diphenhydramine from the dosage form; and, (c) a dosage amount of a first dose of diphenhydramine on the exterior wall surface of the dosage form.
References Cited (Backward Citations)
US3689634A
Cited
US3851648A
Cited
US4200098A
Cited
US4309996A
Cited
US4320759A
Cited
US4298003A
Cited
US4439196A
Cited
US4449983A
Cited
US4609374A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-08-13 | 1994-02-12 | 1994-08-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-08-13 | 1998-02-12 | 1998-08-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-08-13 | 2002-02-12 | 2002-08-14 | $7700.00 | Window Closed / Lapsed |